Jaguar Health, Inc.: Jaguar Health Announces a Special Stock Dividend
Jaguar Health, Inc. (JAGX) announced a special stock dividend of Series R Convertible Preferred Stock to shareholders and warrant holders as of October 13, 2026. The dividend aims to protect against dilution while the company explores strategic alternatives. The preferred stock will convert into common stock on November 2, 2026. Jaguar is focused on developing oral crofelemer for rare intestinal failure diseases, with an expected NDA filing in mid-2027.
How this was made
The 30-second read
Why it matters
The special dividend provides immediate shareholder value and may improve liquidity, but the long-term catalyst remains the pending NDA filing for crofelemer.
Market read
Primary corporate action for a microcap biotech; short-term trading interest around dividend dates.
What to watch
Potential dilution if the preferred shares are later converted; the upcoming NDA filing for crofelemer could dominate price action.
Background
Jaguar Health is a commercial-stage biotech focused on plant-derived therapies for rare intestinal failure diseases.
Ticker impact
Jaguar Health announced a special stock dividend of convertible preferred shares, convertible into common stock, with record date Oct 13 and payment Oct 15.
likely modest upside as investors price in the dividend and conversion terms
New corporate action with clear terms; market typically reacts positively to dividend announcements, especially for microcaps needing shareholder support.
Market effects
May signal confidence in the company's pipeline, modestly supporting the biotech/rare disease sector.
Limited to US-listed microcap investors; no broader regional effect.
Low global impact; primarily relevant to shareholders of Jaguar Health.
Counterpoint
The dividend could be a defensive move masking underlying cash constraints; investors might stay cautious.
Key entities
- CompanyJaguar Health, Inc.
Issuer of the special stock dividend and developer of crofelemer.
- ExecutiveLisa Conte
Founder, President and CEO of Jaguar Health, quoted on the dividend.
